← Leaderboards
Dawn E Quelle
University Of Iowa
$8,297,216
Attributed
$11,008,587
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,333,521 · 12
By mechanism
R01$7,597,387 · 3
P50$6,710,654 · 5
P30$662,480 · 3
R21$363,000 · 1
Top collaborators
- Goutham Narla6 shared
- Benjamin Will Darbro4 shared
- Rebecca D Dodd4 shared
- James R Howe1 shared
- Yusuf Menda1 shared
Most similar at University Of Iowa
Same institution · by research overlap
- James R Howe$4,077,981
- M. Sue Sue O'Dorisio$9,044,145
- Benjamin Will Darbro$699,120
- David L Bushnell$1,807,167
- Rebecca D Dodd$699,120
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorPathway InteractionsMolecularGeneticAutomobile DrivingInsightNeuroendocrine TumorsNeoplasm MetastasisCell ProliferationCell SurvivalProteinsEventOncogenicSignal TransductionBiologicalMouse ModelTumor ProgressionTumor Suppressor ProteinsCellsResponseGenesFundingInnovation
Grant awards (50)
Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer$2,185,934
P50 · FY2025 · CA · contact PI
Role of RABL6A-PP2A in neuroendocrine tumors$515,955
R01 · FY2025 · CA · contact PI
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1$473,531
R01 · FY2025 · NS
Project 1: Improving Immunotherapy in pancreatic NETs$419,863
P50 · FY2025 · CA · contact PI
Administrative Core$225,852
P50 · FY2025 · CA · contact PI
Cancer Genes and Pathways$125,145
P30 · FY2025 · CA · contact PI
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1$510,359
R01 · FY2024 · NS
Role of RABL6A-PP2A in neuroendocrine tumors$503,559
R01 · FY2024 · CA · contact PI
Cancer Genes and Pathways$29,379
P30 · FY2024 · CA · contact PI
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1$544,881
R01 · FY2023 · NS
Role of RABL6A-PP2A in neuroendocrine tumors$528,258
R01 · FY2023 · CA · contact PI
Cancer Genes and Pathways$29,374
P30 · FY2023 · CA · contact PI
Role of RABL6A-PP2A in neuroendocrine tumors$17,974
R01 · FY2023 · CA · contact PI
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1$568,589
R01 · FY2022 · NS
Role of RABL6A-PP2A in neuroendocrine tumors$522,600
R01 · FY2022 · CA · contact PI
Cancer Genes and Pathways$29,374
P30 · FY2022 · CA · contact PI
Role of RABL6A-PP2A in neuroendocrine tumors$537,916
R01 · FY2021 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$99,779
P50 · FY2021 · CA · contact PI
Cancer Genes and Pathways$29,374
P30 · FY2021 · CA · contact PI
Program 1: Cancer Genes and Pathways$299,112
P30 · FY2020 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$189,825
P50 · FY2020 · CA · contact PI
Program 1: Cancer Genes and Pathways$19,504
P30 · FY2020 · CA · contact PI
Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer$2,139,000
P50 · FY2019 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$279,675
P50 · FY2019 · CA · contact PI
Program 1: Cancer Genes and Pathways$19,505
P30 · FY2019 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$298,192
P50 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$19,504
P30 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$7,201
P30 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$6,879
P30 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$4,902
P30 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$3,645
P30 · FY2018 · CA · contact PI
Program 1: Cancer Genes and Pathways$1,699
P30 · FY2018 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$300,301
P50 · FY2017 · CA · contact PI
Program 1: Cancer Genes and Pathways$16,730
P30 · FY2017 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$284,295
P50 · FY2016 · CA · contact PI
Program 1: Cancer Genes and Pathways$21,153
P30 · FY2016 · CA · contact PI
Project 2: Molecular Mechanisms and Biomarkers of Neuroendocrine Tumors$287,938
P50 · FY2015 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$257,962
R01 · FY2011 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$265,940
R01 · FY2010 · CA · contact PI
Novel Suppressors of Pancreatic Cancer$165,000
R21 · FY2010 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$265,940
R01 · FY2009 · CA · contact PI
Novel Suppressors of Pancreatic Cancer$198,000
R21 · FY2009 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$18,222
R01 · FY2009 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$265,940
R01 · FY2008 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$265,940
R01 · FY2007 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$370,587
R01 · FY2006 · CA · contact PI
Growth Inhibition by the ARF Tumor Suppressor$381,564
R01 · FY2005 · CA
Growth Inhibition by the ARF Tumor Suppressor$261,705
R01 · FY2004 · CA
Growth Inhibition by the ARF Tumor Suppressor$261,484
R01 · FY2003 · CA
Growth Inhibition by the ARF Tumor Suppressor$258,481
R01 · FY2002 · CA